Next Article in Journal
Regulation of the Tumor-Suppressor Function of the Class III Phosphatidylinositol 3-Kinase Complex by Ubiquitin and SUMO
Previous Article in Journal
Dynamic Changes in Numbers and Properties of Circulating Tumor Cells and Their Potential Applications
Previous Article in Special Issue
Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder
Article Menu

Export Article

Open AccessReview
Cancers 2014, 6(4), 2387-2403; doi:10.3390/cancers6042387

Met in Urological Cancers

Department of Urology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
*
Author to whom correspondence should be addressed.
Received: 19 June 2014 / Revised: 3 December 2014 / Accepted: 4 December 2014 / Published: 16 December 2014
(This article belongs to the Special Issue MET in Cancer)
View Full-Text   |   Download PDF [637 KB, uploaded 16 December 2014]   |  

Abstract

Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression has been reported to be a useful predictive biomarker for disease progression and patient survival in these malignancies. Many studies have focused on the clinical significance and prognostic role of Met in urological cancers, including prostate cancer (PCa), renal cell carcinoma (RCC), and urothelial cancer. Several preclinical studies and clinical trials are in progress. In this review, the current understanding of the pathological role of Met in cancer cell lines, its clinical significance in cancer tissues, and its predictive value in patients with urological cancers are summarized. In particular, Met-related malignant behavior in castration-resistant PCa and the different pathological roles Met plays in papillary RCC and other histological types of RCC are the subjects of focus. In addition, the pathological significance of phosphorylated Met in these cancers is shown. In recent years, Met has been recognized as a potential therapeutic target in various types of cancer; therapeutic strategies used by Met-targeted agents in urological cancers are summarized in this review. View Full-Text
Keywords: Met; prostate cancer; renal cell carcinoma; urothelial cancer; pathological features; survival; target therapy Met; prostate cancer; renal cell carcinoma; urothelial cancer; pathological features; survival; target therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Miyata, Y.; Asai, A.; Mitsunari, K.; Matsuo, T.; Ohba, K.; Mochizuki, Y.; Sakai, H. Met in Urological Cancers. Cancers 2014, 6, 2387-2403.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top